Bank of New York Mellon Corp cut its stake in shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) by 3.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 450,733 shares of the biopharmaceutical company’s stock after selling 16,496 shares during the period. Bank of New York Mellon Corp owned approximately 0.46% of Celldex Therapeutics worth $1,978,000 as of its most recent filing with the SEC.
Other large investors also recently added to or reduced their stakes in the company. State Street Corp raised its stake in Celldex Therapeutics by 158.9% in the first quarter. State Street Corp now owns 8,561,225 shares of the biopharmaceutical company’s stock worth $32,362,000 after buying an additional 5,254,100 shares during the period. A.R.T. Advisors LLC acquired a new stake in Celldex Therapeutics during the first quarter worth approximately $3,446,000. Norges Bank acquired a new stake in Celldex Therapeutics during the fourth quarter worth approximately $9,378,000. RTW Investments LLC raised its stake in Celldex Therapeutics by 58.2% in the first quarter. RTW Investments LLC now owns 989,376 shares of the biopharmaceutical company’s stock worth $3,740,000 after buying an additional 363,990 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Celldex Therapeutics by 94.9% in the first quarter. JPMorgan Chase & Co. now owns 690,128 shares of the biopharmaceutical company’s stock worth $2,608,000 after buying an additional 336,049 shares during the period. Institutional investors own 78.41% of the company’s stock.
Celldex Therapeutics Inc. (NASDAQ:CLDX) traded down 2.14% on Friday, hitting $4.11. The stock had a trading volume of 943,140 shares. The company’s 50 day moving average is $3.75 and its 200-day moving average is $4.16. Celldex Therapeutics Inc. has a 1-year low of $2.96 and a 1-year high of $18.62. The firm’s market capitalization is $413.24 million.
Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.02. Celldex Therapeutics had a negative net margin of 2,383.60% and a negative return on equity of 47.59%. The company earned $1.39 million during the quarter, compared to the consensus estimate of $0.96 million. During the same period in the previous year, the business earned ($0.33) earnings per share. The firm’s quarterly revenue was down 36.4% on a year-over-year basis. On average, analysts forecast that Celldex Therapeutics Inc. will post ($1.34) EPS for the current year.
A number of research firms recently commented on CLDX. Brean Capital began coverage on Celldex Therapeutics in a research report on Tuesday. They set a “buy” rating and a $16.00 price target on the stock. Jefferies Group restated a “hold” rating and set a $5.00 price target (up from $4.00) on shares of Celldex Therapeutics in a research report on Thursday, August 11th. Finally, Wedbush restated a “neutral” rating and set a $3.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, August 9th. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Celldex Therapeutics currently has a consensus rating of “Hold” and an average price target of $9.75.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.